Herantis Pharma Oyj (HEL: HRTIS)

Herantis Pharma Oyj Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	2023	2022	2021	2020	2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	1.65	1.74	2.65	2.25	2.04	1.4
Other Operating Expenses	-1.46	-1.89	5.18	7.5	5.11	4.71
Operating Expenses	0.19	-0.15	7.99	12.46	8.07	7.16
Operating Income	-0.19	0.15	-7.99	-12.46	-8.07	-7.16
Interest Expense	-	-0.02	-0.07	-0.06	-0.07	-0.07
Interest & Investment Income	0.11	0.04	0	0	0	0.02
Other Non Operating Income (Expenses)	-0.53	0.11	-1.26	-0.24	-1.01	-0.8
EBT Excluding Unusual Items	-0.61	0.28	-9.32	-12.77	-9.15	-8
Pretax Income	-0.61	0.28	-9.32	-12.77	-9.15	-8
Net Income	-0.61	0.28	-9.32	-12.77	-9.15	-8
Net Income to Common	-0.61	0.28	-9.32	-12.77	-9.15	-8
Shares Outstanding (Basic)	19	17	15	10	7	6
Shares Outstanding (Diluted)	19	17	15	10	7	6
Shares Change (YoY)	10.24%	17.34%	43.59%	38.03%	26.51%	18.83%
EPS (Basic)	-0.03	0.02	-0.64	-1.25	-1.24	-1.37
EPS (Diluted)	-0.03	0.02	-0.64	-1.25	-1.24	-1.37
Free Cash Flow	-5.95	-4.64	-8.94	-9.93	-8.56	-5.96
Free Cash Flow Per Share	-0.32	-0.27	-0.61	-0.97	-1.16	-1.02
EBITDA	-	-	-7.99	-12.46	-7.14	-7.04
D&A For EBITDA	-	-	-	-	0.93	0.12
EBIT	-0.19	0.15	-7.99	-12.46	-8.07	-7.16

Source: S&P Capital IQ. Standard template. Financial Sources.